The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for…
By Marilyn S. Albert, Steven DeKosky, Dennis W. Dickson, Bruno Dubois, H. Feldman, Nick C Fox, A. Gamst, D. Holtzman, William J. Jagust, Ronald C. Petersen and 4 more. Alzheimer's & Dementia, 2011
9,421 citations recorded by the source corpus.
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
Subfields: Neurology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/9f79b994b6bbb2da8002582200f6f0b8ba6daf91
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
- Henrik Zetterberg
- Kaj Blennow
- Perminder S. Sachdev
- Kenneth M. Langa
- D. Levine
- Philip Scheltens
- Yaakov Stern
- Daniel Rueckert
In Physiology
- Clifford R. Jack Jr.
- Kaj Blennow
- Henrik Zetterberg
- Richard P. Mayeux
- Yaakov Stern
- Reisa A. Sperling
- Ronald C. Petersen
- William J. Jagust
In Psychiatry and Mental health
- Clifford R. Jack Jr.
- Richard P. Mayeux
- Henrik Zetterberg
- Kaj Blennow
- Yaakov Stern
- Reisa A. Sperling
- Ronald C. Petersen
- David S. Knopman
Citations in the corpus
- Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease (2017, methodology): “Patients met National Institute on Aging–Alzheimer's Association (NIA-AA) criteria for MCI due to AD (n =12; Albert et al., 2011) or probable AD dementia (n = 48; McKhann et al., 2011).”
- Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011, background): “This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
- The diagnosis and management of mild cognitive impairment: a clinical review. (2014, methodology): “Data are adapted from Albert et al. Volume 312, Number 23 jama.com the setting in which the diagnosis is made (eg, primary care, specialist clinic, or general population).”
- National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2011, neutral): “‘‘Alzheimer’s disease’’ refers to a constellation of cognitive and behavioral changes that are typical for patients who have substantial amounts of its hallmark lesions [6, 39].”
- Imaging based enrichment criteria using deep learning algorithms for efficient clinical trials in MCI (2015, background): “All r syndrome with heterogeneous underlying etiology that may not be readily apparent from a clinical workup, posing a major challenge in reliably identifying the most probable beneficiaries of a putative effective treatment [6].”
- Classifying neurocognitive disorders: the DSM-5 approach (2014, methodology): “…discussions with experts from diverse fields to harmonize the DSM criteria with cri‑ teria developed by other expert groups, such as the NIA– AA, 20,27 the frontotemporal dementia expert group, 28,29 the consortium on DLB, 30 the VASCOG working group, 31 the Movement Disorder Study Task Force…”